HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Pliant Therapeutics (NASDAQ:PLRX) but lowered its price target from $52.00 to $48.00. Pliant Therapeutics' shares have fallen 3.74% in the last 24 hours to $16.75. The new price target suggests a potential upside of 186.57%. Pliant Therapeutics is developing bexotegrast for the treatment of fibrosis-related diseases.

February 05, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains Buy rating for Pliant Therapeutics but lowers price target from $52 to $48, indicating a significant potential upside from the current price.
The maintenance of a Buy rating by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook on Pliant Therapeutics' stock, despite the recent price drop and the adjustment of the price target. The significant potential upside to the new target price indicates a strong belief in the company's future performance, particularly in the development of its primary product candidate, bexotegrast. However, the recent decrease in share price and the adjustment of the price target could introduce some volatility in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100